Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model

International Journal of Cancer

Volumn 132, Issue 4, 2012, Pages 967-977

  Zheng, Xiufen ^a,b   Koropatnick, James ^a,b,c   Chen, Di ^a   Velenosi, Thomas ^a   Ling, Hong ^a   Zhang, Xusheng ^a   Jiang, Nan ^a   Navarro, Benjamin ^a   Ichim, Thomas E ^d   Urquhart, Bradley ^a   Min, Weiping ^a,b,c,e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d Medistem Inc   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

breast cancer; dendritic cells; IDO; siRNA

Indexed keywords

DENDRITIC CELL VACCINE; INDOLEAMINE 2,3 DIOXYGENASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE SILENCING; INDOLEAMINE 2,3 DIOXYGENASE GENE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84871390241     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27710     Document Type: Article

References (49)

1. Goxe B, Latour N, Bartholeyns J, et al. Monocyte-derived dendritic cells: development of a cellular processor for clinical applications. Res Immunol 1998; 149: 643-6. (Pubitemid 29487155)
2. Hao S, Bi X, Xu S, et al. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Exp Oncol 2004; 26: 300-6.
3. O'Neill DW, Adams S, Bhardwaj N,. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235-46. (Pubitemid 39331818)
4. Iwashita Y, Goto S, Tominaga M, et al. Dendritic cell immunotherapy with poly(D,L -2,4-diaminobutyric acid)-mediated intratumoral delivery of the interleukin-12 gene suppresses tumor growth significantly. Cancer Sci 2005; 96: 303-7. (Pubitemid 40895079)
5. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32. (Pubitemid 28144092)
6. Draube A, Klein-Gonzalez N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011; 6: e18801.
7. Wobser M, Voigt H, Houben R, et al. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother 2007; 56: 1017-24. (Pubitemid 46675300)
8. Available at: http://www.fda.gov/BiologicsBloodVaccines/ CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm.
9. Yang J, Bernier SM, Ichim TE, et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol 2003; 74: 438-47. (Pubitemid 38040405)
10. Hill JA, Ichim TE, Kusznieruk KP, et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003; 171: 691-6. (Pubitemid 36871378)
11. Zheng X, Koropatnick J, Li M, et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol 2006; 177: 5639-46. (Pubitemid 44527639)
12. Mellor AL, Munn DH,. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003; 170: 5809-13. (Pubitemid 36682557)
13. Grohmann U, Fallarino F, Puccetti P,. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003; 24: 242-8. (Pubitemid 36555962)
14. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3. (Pubitemid 28406294)
15. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867-70. (Pubitemid 35024345)
16. Munn DH, Mellor AL,. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117: 1147-54. (Pubitemid 46718399)
17. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183: 2475-83.
18. Sharma MD, Hou DY, Liu Y, et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113: 6102-11.
19. Orabona C, Grohmann U,. Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol Biol 2011; 677: 269-80.
20. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280-90. (Pubitemid 39071633)
21. Li Y, Xu J, Zou H, et al. 1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs. J Huazhong Univ Sci Technol Med Sci 2010; 30: 344-8.
22. Flatekval GF, Sioud M,. Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase. Immunology 2009; 128: e837-e48.
23. Zheng X, Vladau C, Zhang X, et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009; 113: 2646-54.
24. Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000; 164: 161-7. (Pubitemid 30012986)
25. Elbashir SM, Harborth J, Weber K, et al. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002; 26: 199-213. (Pubitemid 34969582)
26. Zheng X, Suzuki M, Zhang X, et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther 2010; 12: R13.
27. Li M, Zhang X, Zheng X, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol 2007; 178: 5480-7. (Pubitemid 46674342)
28. Krawczyk CM, Holowka T, Sun J, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115: 4742-9.
29. Napoletano C, Pinto D, Bellati F, et al. A comparative analysis of serum and serum-free media for generation of clinical grade DCs. J Immunother 2007; 30: 567-76. (Pubitemid 46988091)
30. Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196: 447-57.
31. Moffett JR, Namboodiri MA,. Tryptophan and the immune response. Immunol Cell Biol 2003; 81: 247-65. (Pubitemid 36904332)
32. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74. (Pubitemid 37279849)
33. Koos D, Josephs SF, Alexandrescu DT, et al. Tumor vaccines in 2010: need for integration. Cell Immunol 2010; 263: 138-47.
34. Elkord E, Alcantar-Orozco EM, Dovedi SJ, et al. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 2010; 10: 1573-86.
35. Schuler G, Schuler-Thurner B, Steinman RM,. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138-47. (Pubitemid 36287518)
36. Morse MA, Lyerly HK,. Clinical applications of dendritic cell vaccines. Curr Opin Mol Ther 2000; 2: 20-8. (Pubitemid 30140201)
37. Berhanu A, Huang J, Alber SM, et al. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. Cancer Res 2006; 66: 4895-903.
38. Osada T, Clay TM, Woo CY, et al. Dendritic cell-based immunotherapy. Int Rev Immunol 2006; 25: 377-413. (Pubitemid 44972272)
39. Munn DH, Mellor AL,. IDO and tolerance to tumors. Trends Mol Med 2004; 10: 15-8. (Pubitemid 38165324)
40. Cerundolo V, Hermans IF, Salio M,. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004; 5: 7-10. (Pubitemid 38081459)
41. Boczkowski D, Nair S,. RNA as performance-enhancers for dendritic cells. Expert Opin Biol Ther 2010; 10: 563-74.
42. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-8. (Pubitemid 32783251)
43. Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164: 3596-9. (Pubitemid 30169812)
44. Fallarino F, Vacca C, Orabona C, et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol 2002; 14: 65-8. (Pubitemid 34083398)
45. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-101. (Pubitemid 35363664)
46. Lee GK, Park HJ, Macleod M, et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002; 107: 452-60. (Pubitemid 36693650)
47. Yan Y, Zhang GX, Gran B, et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 185: 5953-61.
48. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-33. (Pubitemid 43121851)
49. Prasad SJ, Farrand KJ, Matthews SA, et al. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol 2005; 174: 90-8. (Pubitemid 40007395)